|
PDPK1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.23360210935175E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.70600044780667E-10 |
| Normal-vs-Stage2 |
8.981600E-04 |
| Normal-vs-Stage3 |
2.09660067085338E-11 |
| Normal-vs-Stage4 |
8.87049989017896E-10 |
| Stage1-vs-Stage2 |
1.380040E-01 |
| Stage1-vs-Stage3 |
6.582200E-02 |
| Stage1-vs-Stage4 |
8.540200E-02 |
| Stage2-vs-Stage3 |
9.802100E-03 |
| Stage2-vs-Stage4 |
1.710110E-02 |
| Stage3-vs-Stage4 |
9.483200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.03149710994899E-11 |
| Normal-vs-AfricanAmerican |
1.359510E-04 |
| Normal-vs-Asian |
1.46260000000176E-07 |
| Caucasian-vs-AfricanAmerican |
7.231000E-01 |
| Caucasian-vs-Asian |
9.239200E-01 |
| AfricanAmerican-vs-Asian |
6.896200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.18319823225488E-11 |
| Normal-vs-Female |
2.38460029500231E-10 |
| Male-vs-Female |
2.048200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.3028000313613E-09 |
| Normal-vs-Age(41-60Yrs) |
1.84060000574249E-09 |
| Normal-vs-Age(61-80Yrs) |
1.2912004798693E-10 |
| Normal-vs-Age(81-100Yrs) |
5.223300E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.856800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.281000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.253000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.136200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.056800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.773400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.435000E-03 |
| Classical-VS-Follicular |
5.729600E-01 |
| Classical-VS-Other |
1.969420E-01 |
| Classical-VS-Normal |
2.45359954575974E-10 |
| Tall-VS-Follicular |
9.902000E-03 |
| Tall-VS-Other |
7.720200E-01 |
| Tall-VS-Normal |
1.92519999941965E-10 |
| Follicular-VS-Other |
2.127200E-01 |
| Follicular-VS-Normal |
1.83216999999347E-05 |
| Other-VS-Normal |
6.428400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.12599999827034E-08 |
| Normal-vs-N1 |
4.92459961698444E-10 |
| N0-vs-N1 |
5.687800E-02 |
|
|
